CASI PHARMACEUTICALS, INC. Research and Development in Process
CASI PHARMACEUTICALS, INC. (CASIF) reported Research and Development in Process of $6.55 million for the 12-month period ending 2021-12-31, per its 20-F filed 2023-04-26.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2023-04-26
| Period end | Research and Development in Process 12 month |
|---|---|
| 2021-12-31 | $6.55M 20-F · filed 2023-04-26 |
| 2020-12-31 | $17.83M 20-F · filed 2023-04-26 |